According to the Zhitong Finance APP, Tonghua Dongbao (600867.SH) announced that on May 22, 2025, it signed a "Share Transfer Agreement" with Tibet Trust Co., Ltd. (representing "Tibet Trust - Jintong No. 35 Collective Fund Trust Plan") to transfer 23,187,600 unrestricted circulating shares of Tebao Biotechnology (688278.SH) through an agreement transfer, accounting for 5.7% of Tebao Biotechnology's current total share capital, at a transfer price of 56.12 yuan per share, with a total transfer amount of 1.301 billion yuan.

Before this agreement transfer, the company held 65,200,100 shares of Tebao Biotechnology, accounting for 16.03% of Tebao Biotechnology's total share capital. Tonghua Dongbao's transfer of Tebao Biotechnology shares is based on the long-term needs of Tonghua Dongbao's continuous deepening of innovation and transformation development strategy, and is part of an overall arrangement. This move will help to recover funds, improve asset utilization efficiency, and concentrate efforts on developing into an innovative pharmaceutical company, providing financial support for Tonghua Dongbao's layout of innovative drugs, to achieve high-quality and sustainable development for Tonghua Dongbao, and to safeguard the interests of all shareholders of Tonghua Dongbao. At the same time, this agreement transfer of shares will have a significant impact on the company's current profits, and the impact on this year's profits and actual revenue contribution will be subject to the audit results